BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 8697395)

  • 21. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
    de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; van Putten WL; Benraad TJ; Foekens JA
    Br J Cancer; 1999 Mar; 79(7-8):1190-8. PubMed ID: 10098758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
    Speleman L; Kerrebijn JD; Look MP; Meeuwis CA; Foekens JA; Berns EM
    Head Neck; 2007 Apr; 29(4):341-50. PubMed ID: 17163465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
    Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
    Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Plasminogen activator inhibitor 1 and prognosis in breast carcinoma].
    Mayerhofer K; Stolzlechner J; Yildiz S; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeillinger R; Speiser P
    Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):23-7. PubMed ID: 8852782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
    Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
    Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
    Hagiwara H; Sato H; Shirai S; Kobayashi S; Fukumoto K; Ishida T; Seki T; Ariga T; Yano T
    Life Sci; 2006 Apr; 78(19):2249-54. PubMed ID: 16289236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
    Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
    Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
    Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
    Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N; Thomssen C
    Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
    Foekens JA; Ries C; Look MP; Gippner-Steppert C; Klijn JG; Jochum M
    Cancer Res; 2003 Jan; 63(2):337-41. PubMed ID: 12543785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
    Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
    Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
    De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
    Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.